Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston wins second round of stent patent skirmish with Medtronic:

This article was originally published in Clinica

Executive Summary

Shares in Boston Scientific ended last week on the rise after a US court of appeals upheld a previous ruling that found the Natick, Massachusetts company not guilty of infringing patents owned by its arch rival Medtronic. The latter had filed the appeal following a trial in January 2005 when a district court judge ruled that Boston's Taxus Express, Express and NIR stents did not infringe four of Medtronic's patents as claimed by the Minneapolis, Minnesota firm (see Clinica No 1140, p 13). The news led to a 3% rise in Boston's share price, closing at $20.47 last Friday (May 26) while Medtronic's shares dipped 1% to close at $50.26.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT051870

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel